Physician profile
John Henry Smith
NPI 1669402582
$11,849.53
in general payments reported to CMS, 2019-2025
46 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $1,199 · 2021: $2,113 · 2022: $1,856 · 2023: $1,642 · 2024: $2,142 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,272.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,510.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,476.92 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,048.98 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $801.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $667.15 | 2019-2025 | |
| Amgen INC. | $499.20 | 2020-2025 | Repatha, Otezla, Otezla |
| Lundbeck LLC | $424.95 | 2023-2025 | Rexulti |
| Esperion Therapeutics, INC. | $423.89 | 2020-2024 | Nexletol, Nexlizet |
| Glaxosmithkline, LLC. | $397.88 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.88 | 2019-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $309.88 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $307.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $274.43 | 2020-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.07 | 2020-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $231.28 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.